| 27th week of 2013 patent applcation highlights part 39 |
| Patent application number | Title | Published |
|---|
| 20130171082 | EXTRACT OF THE ABOVE-GROUND PORTIONS OF GYNANDROPSIS GYNANDRA OR CLEOME GYNANDRA, AND COSMETIC, DERMATOLOGICAL OR PHARMACEUTICAL COMPOSITIONS INCLUDING SAME - The invention relates to a composition, such as a cosmetic, dermatological, or pharmaceutical composition, including an extract of the above-ground portions of | 2013-07-04 |
| 20130171083 | PHOTO-CURABLE COSMETIC COMPOSITIONS - Disclosed herein are cosmetic compositions comprising (1) at least one polyvinyl alcohol-styrylpyridinium polymer and (2) at least one latex film-forming polymer. Also disclosed herein are methods for making up and/or enhancing the appearance of a keratinous substrate comprising (1) forming a film on the keratinous substrate by applying to said keratinous substrate a cosmetic composition comprising (a) at least one polyvinyl alcohol-styrylpyridinium polymer and (2) at least one latex film-forming polymer and (2) exposing the film to radiation chosen from UV and visible light radiation. | 2013-07-04 |
| 20130171084 | COMPOSITIONS CONTAINING A SILICON RESIN AND AN ACRYLIC FILM FORMING AGENT - The invention relates to a composition, especially a cosmetic composition, comprising at least one silicon resin comprising at least one T unit and at least one acrylic film forming agent, as well as to methods of using such compositions. | 2013-07-04 |
| 20130171085 | AMINO ACID DERIVATIVES; COMPOSITIONS CONTAINING THEM; USE AS AGENTS FOR TREATING HUMAN PERSPIRATION - The invention relates to novel compounds derived from amino acids of formula (I) | 2013-07-04 |
| 20130171086 | ANTIPERSPIRANT COMPOSITIONS AND METHODS FOR PREPARING ANTIPERSPIRANT COMPOSITIONS - Antiperspirant compositions with improved efficacy for shaving and methods for preparing the same are provided. In an exemplary embodiment, an antiperspirant composition includes an active antiperspirant compound, a hair minimizing compound, and a skin lubricating compound. In another exemplary embodiment, a method for preparing an antiperspirant composition includes combining an active antiperspirant compound, a suspending agent, and a carrier at a first temperature to form a mixture and cooling the mixture to form a cooled mixture having a second temperature that is lower than the first temperature. The exemplary method further includes combining a hair minimizing compound and a skin lubricating compound to the mixture and pouring the mixture into a mold at a third temperature that is lower than the second temperature. | 2013-07-04 |
| 20130171087 | COMPOSITION COMPRISING MIXTURES OF ISOSTEARAMIDE, GLYCEROL ESTER AND WATER - The present invention is directed to compositions comprising a mixture comprising at least one isostearamide, at least one glycerol ester and water, and also to the use of these compositions as thickeners or shampoos, conditioners, shower gels, body cleaning compositions or skin cleaning compositions or for producing shampoos, conditioners, shower gels, body cleaning compositions or skin cleaning compositions. | 2013-07-04 |
| 20130171088 | COMBINED STABLE CATIONIC AND ANIONIC SURFACTANT COMPOSITIONS - Aqueous free-flowing surfactant compositions having non-Newtonian shear thinning properties are disclosed. These stable compositions include both cationic and anionic surfactants and can suspend water-insoluble particles or partially insoluble components. | 2013-07-04 |
| 20130171090 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. | 2013-07-04 |
| 20130171091 | Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent. | 2013-07-04 |
| 20130171092 | ALPHA-CYANOACRYLATE ESTER SYNTHESIS - The high temperatures required for cracking the cyanoacrylate oligomers, produced by the Knovenagel condensation of formaldehyde and a cyanoacetate, limit the synthetic diversity and the number of different side chains that can be incorporated into a cyanoacrylate prepared using this method. Accordingly, the diversity of cyanoacrylate monomers prepared industrially is quite limited. Disclosed herein is a method for the preparation of alpha-Cyanoacrylate ester monomers from a variety of phosphonium and ammonium alpha-cyanoacrylate salts. The phosphonium and ammonium alpha-cyanoacrylate salts are of the general formula: | 2013-07-04 |
| 20130171093 | HEALING POWDER AND METHOD OF USE THEREOF - A wound healing powder, comprising a sugar selected from the group consisting of one or more pharmaceutically acceptable monosaccharides and disaccharides, in an amount of at least 25% by weight of the powder mixture; and an absorbent agent which forms a bioabsorbable biocompatible matrix with wound secretions, comprising a polymer formed of one or more of saccharide or saccharide derivative monomers and lactic acid monomers, in an amount of at least 25% by weight of the powder mixture. | 2013-07-04 |
| 20130171094 | USE OF VANADIUM COMPOUNDS TO ACCELERATE BONE HEALING - This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment. | 2013-07-04 |
| 20130171095 | Method for Purifying Antibodies - The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains. | 2013-07-04 |
| 20130171096 | IMMUNOBINDERS DIRECTED AGAINST SCLEROSTIN - Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions. | 2013-07-04 |
| 20130171097 | METHOD FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS - The present invention relates to a method for the prophylactic and/or therapeutic treatment of glucocorticoid induced osteoporosis comprising maintaining or restoring AP-1 activity or AP-1-mediated effects, for example by LIF treatment. The method may additionally comprise a method for the treatment of a medical condition associated with inflammation comprising inhibition of NF-KB activity, for example by glucocorticoid (GC) treatment. The present invention therefore also relates to a method for the treatment and/or prevention of glucocorticoid induced osteoporosis comprising the administration of an effective amount of LIF to a subject, preferably in combination with GC treatment. | 2013-07-04 |
| 20130171098 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 2013-07-04 |
| 20130171099 | TREATMENT OF T-CELL MEDIATED IMMUNE DISORDERS - A method for suppressing T cell activation which comprises contacting a cell population comprising T cells in vitro or ex viva with an effective amount of STRO-1 | 2013-07-04 |
| 20130171100 | USE OF INTERLEUKIN-22 IN TREATING VIRAL HEPATITIS - This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis. | 2013-07-04 |
| 20130171101 | 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections - Surprising antiviral activity of 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone (Compound 1) was reported in the treatment or prevention of viral infections, particularly in combination with other antiviral agents such as interferon and/or ribavarin. | 2013-07-04 |
| 20130171102 | HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS - The invention is related to anti-viral compounds of formula (A) as defined in the claims, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well to processes and intermediates useful for preparing such compounds. | 2013-07-04 |
| 20130171103 | METHODS FOR TREATING VIRAL CONDITIONS - Compounds that selectively inhibit viral replication or the production of viral RNA or DNA, viral protein or virus induced cytopathic effects and compositions comprising such Compounds are described. Also described are methods of inhibiting viral replication or the production of viral RNA or DNA, viral protein or virus induced cytopathic effects using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments. | 2013-07-04 |
| 20130171104 | SYNERGISTIC ACTIVITY OF MODULATORS OF THE NO METABOLISM AND OF NADPH OXIDASE IN THE SENSITIZATION OF TUMOR CELLS - What is disclosed is pharmaceutical compositions which contain a pharmaceutically active amount of at least one active substance which increases the available NO concentration in the cell, together with at least one active substance which stimulates the NADPH oxidase. | 2013-07-04 |
| 20130171105 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR - A pharmaceutical combination comprising a topoisomerase II inhibitor, and an Hsp90 inhibitor according to the following formulae a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein. | 2013-07-04 |
| 20130171106 | USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT - The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R. | 2013-07-04 |
| 20130171107 | LONG LASTING DRUG FORMULATIONS - The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha. | 2013-07-04 |
| 20130171108 | USE OF ANTI THIRD PARTY CENTRAL MEMORY T CELLS FOR ANTI-LEUKEMIA/LYMPHOMA TREATMENT - A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject. | 2013-07-04 |
| 20130171109 | ROTHIA SPECIES GLUTEN-DEGRADING ENZYMES AND USES THEREOF - There are gluten-degrading enzymes found in | 2013-07-04 |
| 20130171110 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING PLURIPOTENT STEM CELLS INTO PRIMITIVE BLOOD CELLS AND USES THEREOF - Compositions and methods that employ various combinations of such factors as retinoic acid signaling inhibitors, antioxidants, BMP4, VEGF, prostaglandin E | 2013-07-04 |
| 20130171111 | METHOD OF MANUFACTURING A SCAFFOLD FOR TISSUE ENGINEERING OR REPAIR - The invention relates to a method of manufacturing a scaffold for tissue engineering or repair. The method includes providing a mixture comprising a degradable hydrogel, a degradable particle, and living cells. The mixture is then incubated under conditions which allow proliferation of the living cells and degradation of the degradable particle in the hydrogel. The degradable hydrogel of the incubated mixture is then degraded at least partially, followed by adding further living cells to obtain the scaffold. | 2013-07-04 |
| 20130171112 | Methods for promoting hair growth - The invention is directed to methods for promoting hair growth. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 2013-07-04 |
| 20130171113 | METHOD OF TREATING GRAFT VERSUS HOST DISEASE - A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1 | 2013-07-04 |
| 20130171114 | ISLETS OF LANGERHANS TRANSPLANT USING ISLETS OF LANGERHANS AND ADIPOSE TISSUE DERIVED STEM CELLS - An object of the present invention is to provide a pancreatic islet transplantation technique that enables increase of graft survival rate of pancreatic islets after pancreatic islet transplantation, to maintain survival of pancreatic islets, and to reduce the number of transplanted pancreatic islets required for normalizing blood glucose level. When performing pancreatic islet transplantation, by transplanting pancreatic islets and adipose tissue-derived stem cells together, it is possible to significantly improve graft survival rate of transplanted pancreatic islets, and reduce by half the number of transplanted pancreatic islets required for normalizing blood glucose level. | 2013-07-04 |
| 20130171116 | OPTICALLY SENSITIVE CELL NETWORK - A neural network is disclosed. The neural network comprises a plurality of optogenetically modified neural cells being three-dimensionally distributed in a hydrogel medium and being disconnected from any solid support having a shear modulus above 1 GPa. | 2013-07-04 |
| 20130171117 | Lactobacilli with Anti-Oxidant Action - The present invention relates to specific | 2013-07-04 |
| 20130171118 | INTESTINAL PROTECTANT - The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient. | 2013-07-04 |
| 20130171119 | SKIN CARE COMPOSITIONS - Dermatological and cosmetic compositions and methods are provided to reduce the appearance of biological and/or environmentally-caused aging. | 2013-07-04 |
| 20130171120 | COMPOSITION FOR ENHANCING PHYSICAL PERFORMANCE - This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin. | 2013-07-04 |
| 20130171121 | MATURATION OF GASTROINTESTINAL TRACT - The present invention provides a method to induce maturation of an immature GI-tract, such as intestine, e.g. small intestine, the method comprising the steps of administering a mixture of enzymes to the immature GI-tract, said enzymes having a pancreatic activity or action, and/or pancreatic like activity or action, and analysing the maturation process of the GI-tract to monitor said maturation process. Provided herein are also uses and kits to provide for GI-tract maturation. | 2013-07-04 |
| 20130171122 | ENDOPEPTIDASE AND NEUROTOXIN COMBINATION TREATMENT OF BLADDER DISORDERS - The present specification discloses Clostridial neurotoxins and TEMs, compositions comprising such Clostridial neurotoxins and TEMs, kits comprising such Clostridial neurotoxins, TEMs and/or compositions, methods of treating a bladder disorder in an individual using such Clostridial neurotoxins, TEMs and/or compositions, use of such Clostridial neurotoxins and TEMs in manufacturing a medicament for treating a bladder disorder, and uses of such Clostridial neurotoxins, TEMs and/or compositions in treating a bladder disorder. | 2013-07-04 |
| 20130171123 | METHODS FOR PURIFICATION, USE AND ANALYSIS OF FERRITIN - This invention provides methods of isolating ferritin from plant and animal material. The isolated ferritin can be administered to humans or animals in need of iron, and can be used to treat or supplement iron deficiency. The isolated ferritin can be used in industrial applications, such as increasing the iron content in heat-processed food or beverages. The methods of the invention also include quantitation of iron derived from plant or animal ferritin. | 2013-07-04 |
| 20130171124 | Compositions And Methods Of Treating Head And Neck Cancer - The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function. | 2013-07-04 |
| 20130171125 | Methods for the Regulation of Cellular Metabolism Through the Modulation of SIRT3 Activity - The present invention relates to methods of preventing or treating cancer and/or decreasing damage to organs or tissues exposed to hypoxic conditions through the use of agents that modulate the expression or activity of SIRT3. | 2013-07-04 |
| 20130171126 | CROSSLINKED POLYSACCHARIDE BEADS AND THEIR BIOMEDICAL USES - The present inventions relates to beads as biocompatible material adapted for use within the human or animal body. Said beads are highly useful for tissue engineering, in situ tissue regeneration, as well as for drug and/or cells delivery. In addition, said beads may support biotechnological applications such as cell carriers. | 2013-07-04 |
| 20130171127 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE - The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue. | 2013-07-04 |
| 20130171128 | REDUCING VISCOSITY OF PHARMACEUTICAL FORMULATIONS - A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from taurine, theanine, sarcosine, citrulline and betaine. | 2013-07-04 |
| 20130171129 | CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES THEREFOR - A stable immunogenic or vaccine composition comprising a complex or polyhedra comprising same comprising an antigen of a pathogen or other antigen against which a immune response is sought in a human or non-human animal subject and a polyhedrin protein derived from a cytoplasmic polyhedrosis virus (CPV), Delivery of the complex to a subject in substantially polyhedral form induces an immune response thereto. Methods of using same to elicit an immune response. | 2013-07-04 |
| 20130171130 | SOLUBLE INTERLEUKIN-20 RECEPTOR - A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond. | 2013-07-04 |
| 20130171131 | Soluble Forms of Hendra and Nipah Virus G Glycoprotein - This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses. | 2013-07-04 |
| 20130171132 | Soluble Forms of Hendra and Nipah Virus G Glycoprotein - This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses. | 2013-07-04 |
| 20130171133 | CANCER METHODS - A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule which encodes the OPCML polypeptide or fragment or variant thereof. | 2013-07-04 |
| 20130171134 | NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES - The present invention provides methods for improving treatment effect in a patient suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”), by treatment with bevacizumab (Avastin®) in combination with a chemotherapy regimen by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). The improved treatment effect may be improved overall survival or improved progression free survival. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). | 2013-07-04 |
| 20130171135 | METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY - The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2013-07-04 |
| 20130171136 | Methods of Treating Giant Cell Arteritis With Anti-TNF Alpha Antibodies - Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided. | 2013-07-04 |
| 20130171137 | METHODS OF TREATING AUTOIMMUNE DISEASES WITH ANTI-FCERI ANTIBODIES - Methods of using anti-FceRI or anti-IgE antibodies for treating an autoimmune disease are disclosed. Also disclosed is a composition comprising an anti-FceRI antibody or anti-IgE antibody for use in treating an autoimmune disease. Also disclosed are non-antibody compounds that specifically activate basophils and/or mast cells, either by cross-linking IgE or FceRI, or by activating the cells through an FceRI-independent pathway and methods of using the same to treat autoimmune diseases. | 2013-07-04 |
| 20130171138 | Immunoglobulin Chimeric Monomer-Dimer Hybrids - The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention. | 2013-07-04 |
| 20130171139 | NCAM-VASE AND NEURODEGENERATION - Inhibitors of NCAM-VASE, compositions comprising said inhibitors, and methods of using said inhibitors for stimulation of neuroplasticity and/or neuroregeneration in the central nervous system, and for increasing neuronal cell response to agents that stimulate neuroplasticity and/or neuroregeneration in the central nervous system, are provided. The inhibitor or composition may be used, for example, for treating brain or spinal cord injury; schizophrenia, motor neurone disease; a neurodegenerative disorder such as Alzheimer's disease, multiple sclerosis or Parkinson's disease; ischaemia caused by stroke; or for improving learning and/or memory. | 2013-07-04 |
| 20130171140 | HOMODIMERIC PROTEIN CONSTRUCTS - The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins. | 2013-07-04 |
| 20130171141 | COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS - The invention relates to a combination which comprises:
| 2013-07-04 |
| 20130171142 | METHODS OF USING ANTI-CD3 ANTIBODIES TO PREVENT WEIGHT GAIN - Provided herein are methods of administering anti-CD3 antibodies or antigen binding fragments to a human for decreasing weight gain or increasing weight loss. In certain embodiments, the human exhibits a body mass index (BMI) or greater than or equal to about 27. In certain embodiments, the anti-CD3 antibody or antigen binding fragment does not bind or has reduced binding to at least one class of Fc (gamma) receptor. | 2013-07-04 |
| 20130171143 | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF ALPHA - The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed. | 2013-07-04 |
| 20130171144 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. | 2013-07-04 |
| 20130171145 | METHODS OF TREATING LIVER DISEASE - Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors. | 2013-07-04 |
| 20130171146 | DUAL-SPECIFIC IL-1A/ IL-1B ANTIBODIES - The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-1α and human IL-1β. The dual specific antibodies of the invention also neutralize both human IL-1α and human IL-1β. The invention also provides domain antibodies (dAbs) specific for human IL-1α and human IL-1β. | 2013-07-04 |
| 20130171147 | NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE - The present invention is directed to the neutralizing prolactin receptor antibody 002-H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling. | 2013-07-04 |
| 20130171148 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE - Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 2013-07-04 |
| 20130171149 | Anti-ANGPTL3 Antibodies and Uses Thereof - A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like. | 2013-07-04 |
| 20130171150 | FELINE PICORNA VIRUS AND USES THEREOF - The invention is directed to a Feline Picorna Virus, an isolated nucleic acid and amino acid sequences therefrom, and uses thereof. | 2013-07-04 |
| 20130171151 | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease - Aspects of the invention provide methods for treatment of nonalcoholic steatohepatitis and associated liver fibrosis. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate compound for the treatment of nonalcoholic steatohepatitis and associated liver fibrosis. | 2013-07-04 |
| 20130171152 | ANTIBODIES TO MUC16 AND METHODS OF USE THEREOF - The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer. | 2013-07-04 |
| 20130171153 | PROTEINS THAT BIND PI16 AND USES THEREOF - The present disclosure provides an isolated protein comprising at least one antibody variable region that is capable of binding to peptidase inhibitor 16 (PI16), wherein the protein is also capable of competitively inhibiting binding of an antibody produced by a hybridoma designated CRCBT-02-001 deposited with the ATCC under Accession Number PTA-10685 to PI16. The present invention also provides use of the protein, e.g., in diagnosis, therapy or to isolate cells, preferably Treg cells. | 2013-07-04 |
| 20130171154 | ANTI-CD38 ANTIBODIES - Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies. | 2013-07-04 |
| 20130171155 | Inhibitors Of Complement Activation - The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) | 2013-07-04 |
| 20130171156 | BMP-1 Procollagen C-Proteinase for Diagnosis and Treatment of Bone and Soft Tissue Defects and Disorders - Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3. | 2013-07-04 |
| 20130171157 | NOGO Receptor-Mediated Blockade of Axonal Growth - Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease. | 2013-07-04 |
| 20130171158 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 - A method of treating or preventing an abnormality of glucose metabolism in a subject, the method comprising administering an antagonist of Inhibitor of Differentiation 1 (Id1) to the subject. | 2013-07-04 |
| 20130171159 | PHOSPHORYLATED TWIST1 AND METASTASIS - The present application relates to methods for metastasis in a subject by modulating the phosphorylation of the Serine 42 of Twist1 by administering to said subject a therapeutically effective amount of a modulator of said phosphorylation of the Serine 42 of Twist1. Antibodies, uses methods and biomarkers based on the | 2013-07-04 |
| 20130171160 | ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF - Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies. | 2013-07-04 |
| 20130171161 | METHOD AND COMPOSITION FOR THE TREATMENT OF DISEASES CAUSED BY OR ASSOCIATED WITH HIV - The invention provides a combination pharmaceutical composition comprising a) at least one activated-potentiated form of an antibody to at least one cytokine or at least an activated-potentiated form of an antibody to at least one receptor; and b) an effective amount of a nucleoside reverse transcriptase inhibitor, wherein said at least one cytokine or at least one receptor is participating in the regulation of immune process. Various embodiments and variants are contemplated. | 2013-07-04 |
| 20130171162 | COMPOSITIONS AND METHODS FOR THE PREVENTION OF OXIDATIVE DEGRADATION OF PROTEINS - The invention relates to pharmaceutical formulations comprising a protein and free methionine in combination with one or more compounds capable of preventing the oxidation of aromatic amino acid residues within a protein. More specifically, the invention relates to stabilized, pharmaceutically effective preparations of oxidation-sensitive therapeutic agents. The invention further relates to a method of inhibiting the oxidation of such therapeutic agents. | 2013-07-04 |
| 20130171163 | Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis - The present invention relates to the regulation of angiogenesis and arteriogenesis by leukocyte antigen-related protein tyrosine phosphatase (LAR). The invention further relates to the use of inhibitors of LAR expression and/or activity to stimulate angiogenesis and/or arteriogenesis. | 2013-07-04 |
| 20130171164 | COMPOSITIONS AND METHODS OF MODULATING RECEPTOR PROTEIN TYROSINE PHOSPHATASES - Provided herein, inter alia, are compositions and methods of measuring levels of RPTP protein and RNA and treating subjects with certain diseases, such as autimmune diseases. | 2013-07-04 |
| 20130171165 | PREPARATION OF SCFV ANTIBODY FRAGMENTS - The invention relates to methods of preparing antibody fragments. The invention further relates to antibody fragments prepared by these methods. The invention further relates to antibody variable regions comprised in antibody fragments producible by these methods. | 2013-07-04 |
| 20130171166 | BIOMARKERS - The invention relates to a method of diagnosing or monitoring major depressive disorder using MMP-3 as a biomarker. | 2013-07-04 |
| 20130171167 | Methods of Using IL-1beta Compounds - This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans. | 2013-07-04 |
| 20130171168 | Human Anti-OPGL Neutralizing Antibodies as Selective OPGL Pathway Inhibitors - Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided. | 2013-07-04 |
| 20130171169 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease. | 2013-07-04 |
| 20130171170 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR - Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided. | 2013-07-04 |
| 20130171171 | PROSTAGLANDIN TRANSPORTER INHIBITORS - The present invention generally relates to prostaglandin transport. More specifically, the invention is directed to compounds that inhibit prostaglandin transport and subsequent COX-2 induction, and methods relating thereto. | 2013-07-04 |
| 20130171172 | CALPAIN-3 INHIBITORS FOR TREATING MUSCULAR DYSTROPHIES AND CARDIOMYOPATHIES - A composition comprising a calpain-3 inhibitor for treating muscular dystrophies and cardiomyopathies, in particular tibial muscular dystrophy (TMD). | 2013-07-04 |
| 20130171173 | METHOD FOR PRONGF ASSAY FOR IN VITRO DIAGNOSIS OF CANCER IN PARTICULAR BREAST, THYROID OR LUNG CANCER AND THERAPEUTIC USE OF PRONGF - A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer. | 2013-07-04 |
| 20130171174 | ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY AND USES THEREOF - An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided. | 2013-07-04 |
| 20130171175 | Factor IX Polypeptides and Methods of Use Thereof - The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 2013-07-04 |
| 20130171176 | Anthracycline-Antibody Conjugates for Cancer Therapy - The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety. | 2013-07-04 |
| 20130171177 | Therapeutic Use of Neural Stem Cells - The present invention provides an isolated cell obtainable from the CTX0E03 neural stem cell line for use in the treatment of a disorder associated with elevated levels of pro-inflammatory cytokines, wherein the disorder is selected from unipolar and bipolar depression, schizophrenia, obsessive compulsive disorder, autism and autistic syndrome disorders. | 2013-07-04 |
| 20130171178 | Immunogenic Peptides of Xage-1 - XAGE-1 is a gene expressed in a number of important human cancers, including prostate cancer, lung cancer, breast cancer, ovarian cancer, glioblastoma, pancreatic cancer, and melanoma. It has now been discovered that peptides of fifty or fewer amino acids comprising the sequence X | 2013-07-04 |
| 20130171179 | RECOMBINANT T-CELL RECEPTOR LIGANDS WITH COVALENTLY BOUND PEPTIDES - Disclosed herein are stable complexes including an MHC class I or MHC class II recombinant T cell receptor ligand RTL polypeptide covalently linked to an antigenic determinant by a disulfide bond. Also disclosed are methods of making such compositions and methods of use, for example to treat or inhibit a disorder, for example, an autoimmune disorder. | 2013-07-04 |
| 20130171180 | DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE - The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, as well as to their process of preparation, their use in the peptide synthesis, said peptide and the use of said peptide. | 2013-07-04 |
| 20130171181 | DPS FUSION PROTEINS FOR USE IN VACCINES AND DIAGNOSTICS - Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA-binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products. | 2013-07-04 |
| 20130171182 | INFLUENZA VACCINE - The invention provides a protein comprising a first and a second copy of hepatitis B core antigen (HBcAg) in tandem, in which one or both of the copies of HBcAg comprises influenza virus A surface polypeptide M2 or a fragment thereof in the e | 2013-07-04 |
| 20130171183 | COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIANTS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2013-07-04 |
